中生製藥(01177.HK)抗腫瘤藥獲海外III期臨床陽性結果
中生製藥(01177.HK)公布,集團自主研發的抗腫瘤藥「鹽酸安羅替尼膠囊」(商品名:福可維),用於治療實體瘤患者III期臨床試驗結果在2021美國臨床腫瘤學會年會上獲口頭報告,成為中國首個在實體腫瘤領域獲得海外註冊III期臨床研究陽性結果的創新藥。
安羅替尼在該年會上首次披露多種晚期軟組織肉瘤的APROMISS III期臨床試驗結果,數據顯示,與目前在美國用於治療軟組織肉瘤的藥物達卡巴秦對照組相比,安羅替尼在晚期滑膜肉瘤患者的治療中有更好的疾病控制和更高的無進展生存期。而安羅替尼已在中國獲批准用於治療晚期非小細胞肺癌、軟組織肉瘤、小細胞肺癌、甲狀腺髓樣癌四大適應症。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.